Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well vorinostat works in treating patients with
progressive or recurrent glioblastoma multiforme. Drugs used in chemotherapy, such as
vorinostat, work in different ways to stop the growth of tumor cells, either by killing the
cells or by stopping them from dividing. Vorinostat may also stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth. Giving vorinostat before surgery may
make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
Giving it after surgery may kill any remaining tumor cells.